Key result
Platelet function testing requires diagnostic measures for pharmacodynamics and prognostic measures for risk stratification.
Why the study?
How should the clinical usefulness of platelet function testing be evaluated in patients taking P2Y12 inhibitors?
How should the clinical usefulness of platelet function testing be evaluated in patients taking P2Y12 inhibitors?
When evaluating platelet function testing, prognostic performance measures like hazard ratios are more appropriate than diagnostic measures like sensitivity and specificity for assessing future thrombotic risk.
No takes yet. Share an insight, caveat, or question.
Platelet function testing confirms P2Y12 inhibitor effect linked to lower thrombosis; leaves open whether routine testing improves outcomes.
Price et al. (2012) conducted a review in Patients taking P2Y12 inhibitors. Platelet function testing was evaluated. Platelet function testing should be evaluated using diagnostic measures for pharmacodynamic effects and prognostic measures like hazard ratios for risk stratification.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: